David Williams

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball, Martin M. Okun, David Williams et al. · New England Journal of Medicine · 2016 · 777 citations

Medicine, Dermatology, Pharmacology +16

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Kristian Reich, Melinda Gooderham, Diamant Thaçi et al. · The Lancet · 2019 · 298 citations

Life Sciences, Clinical Sciences, Immunology +11

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham et al. · JAMA Dermatology · 2020 · 216 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

Alexa B. Kimball, Jeffrey M. Sobell, Christos C. Zouboulis et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 193 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Christos C. Zouboulis, Martin M. Okun, Errol P. Prens et al. · Journal of the American Academy of Dermatology · 2018 · 187 citations

Medicine, Immunology, Pharmacotherapy +7